New hope for advanced lung cancer: chemo-radiation combo enters trial
NCT ID NCT07547332
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of nab-paclitaxel (a chemotherapy drug) and local radiation therapy for people with extensive-stage small-cell lung cancer whose disease has worsened after initial treatment. The study aims to see if this combo can improve progression-free survival and overall survival. About 84 participants will receive up to 6 cycles of nab-paclitaxel plus optional radiation, with the goal of finding a better second-line option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nab-paclitaxel (a chemotherapy drug) combined with local radiation therapy
What this could lead to
If it works, this could offer a new second-line treatment option for people with advanced small-cell lung cancer, potentially improving tumor control and survival.
What could go wrong
This is an early-phase, single-arm study with no comparison group, so results may not be definitive. The combination may cause side effects like bone marrow suppression, and not all patients may benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••